Mogamulizumab
| Evidence Level: L5 | Predicted Indications: 58 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Mogamulizumab |
| DrugBank ID | DB12498 |
| Brand Names (EU) | Poteligeo |
| Evidence Level | L5 |
| Predicted Indications | 58 |
| Top Prediction Score | 99.44% |
Approved Indication (EMA)
Poteligeo is indicated for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | prostatic urethra urothelial carcinoma | 99.44% | DL |
| 2 | kidney pelvis sarcomatoid transitional cell carcinoma | 99.42% | DL |
| 3 | infiltrating bladder urothelial carcinoma sarcomatoid variant | 99.40% | DL |
| 4 | renal pelvis papillary urothelial carcinoma | 99.37% | DL |
| 5 | human herpesvirus 8-related tumor | 99.24% | DL |
| 6 | ectomesenchymoma | 99.15% | DL |
| 7 | malignant cutaneous granular cell skin tumor | 99.15% | DL |
| 8 | middle ear neuroendocrine tumor | 99.00% | DL |
| 9 | transitional cell carcinoma | 98.98% | DL |
| 10 | Richter syndrome | 98.56% | DL |
| 11 | metastatic neoplasm | 98.33% | DL |
| 12 | malignant spiradenoma | 98.30% | DL |
| 13 | HER2 positive breast carcinoma | 97.67% | DL |
| 14 | cutaneous neuroendocrine carcinoma | 96.95% | DL |
| 15 | normal breast-like subtype of breast carcinoma | 96.77% | DL |
| 16 | progesterone-receptor positive breast cancer | 96.77% | DL |
| 17 | localized pagetoid reticulosis | 96.75% | DL |
| 18 | progesterone-receptor negative breast cancer | 96.71% | DL |
| 19 | breast tumor luminal A or B | 96.59% | DL |
| 20 | liver neuroendocrine carcinoma | 96.22% | DL |
Showing top 20 of 58 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.